This Article Full Text (PDF) All Versions of this Article: 0885066608326970v1 24/1/47    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Li Yumin Articles by Frezza, E.E. Search for Related Content PubMed PubMed Citation Articles by Li Yumin, Articles by Frezza, E.E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Sepsis Social Bookmarking                         What's this?

A New Immunomodulatory Therapy for Severe Sepsis: Ulinastatin Plus Thymosin 1

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China

Chen Hao

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China

Li Xun

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China

Zhou Wence

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China

He Minyan, MS

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China

M. Chiriva-Internati

Departments of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, Texas

M.S. Wachtel

Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas

E.E. Frezza, MD

Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, Texas, eldo.frezza{at}ttuhsc.edu

Objectives: To study the effect of immunomodulatory therapy with ulinastatin plus thymosin ₁ on septic patients. Method: A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo. Acute Physiology and Chronic Health Evaluation II scores, clinical data, lymphocyte subsets, immunological indexes, and coagulation parameters were determined before admission and on the 3rd, 8th, and 28th day after admission to the Intensive Care Unit. Results: The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters, and cytokine levels in the treatment. Conclusions: Combined immunomodulatory therapy with ulinastatin plus thymosin ₁ appears to yield improved survival for patients with sepsis; this finding should be verified in larger clinical trials.

Key Words: sepsis • ulinastatin • thymosin 1 • clinical trial • immunomodulatory therapy • APACHE II

This version was published on January 1, 2009

Journal of Intensive Care Medicine, Vol. 24, No. 1, 47-53 (2009)
DOI: 10.1177/0885066608326970


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Kapoor The Rapidly Expanding Therapeutic Role of Thymosin {alpha}-1 in the Management of Gastrointestinal and Systemic Infectious Disorders J Intensive Care Med, May 1, 2009; 24(3): 210 - 211. [PDF]